Literature DB >> 7688765

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

A E Thigpen1, R I Silver, J M Guileyardo, M L Casey, J D McConnell, D W Russell.   

Abstract

The synthesis of dihydrotestosterone is catalyzed by steroid 5 alpha-reductase isozymes, designated types 1 and 2. Mutation of type 2 results in male pseudohermaphroditism, in which the external genitalia are phenotypically female at birth. Two striking and unexplained features of this disorder are that external genitalia of affected males undergo virilization during puberty and that these individuals have less temporal hair regression. The tissue-specific and developmental expression patterns of the 5 alpha-reductase isozymes were investigated by immunoblotting. The type 1 isozyme is not detectable in the fetus, is transiently expressed in newborn skin and scalp, and permanently expressed in skin from the time of puberty. There was no qualitative difference in 5 alpha-reductase type 1 expression between adult balding vs. nonbalding scalp. The type 2 isozyme is transiently expressed in skin and scalp of newborns. Type 2 is the predominant isozyme detectable in fetal genital skin, male accessory sex glands, and in the prostate, including benign prostatic hyperplasia and prostate adenocarcinoma tissues. Both isozymes are expressed in the liver, but only after birth. These results are consistent with 5 alpha-reductase type 1 being responsible for virilization in type 2-deficient subjects during puberty, and suggest that the type 2 isozyme may be an initiating factor in development of male pattern baldness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688765      PMCID: PMC294929          DOI: 10.1172/JCI116665

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

Authors:  P C Walsh; J D Madden; M J Harrod; J L Goldstein; P C MacDonald; J D Wilson
Journal:  N Engl J Med       Date:  1974-10-31       Impact factor: 91.245

3.  Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.

Authors:  C B Brendler; A L Follansbee; J T Isaacs
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

4.  Regulation of human hair growth by steroid hormones. I. Testerone metabolism in isolated hairs.

Authors:  H U Schweikert; J D Wilson
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

5.  Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor.

Authors:  D W Russell; W J Schneider; T Yamamoto; K L Luskey; M S Brown; J L Goldstein
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

6.  Testosterone and epitestosterone metabolism of single hairs in 5 patients with 5 alpha-reductase-deficiency.

Authors:  J A Schmidt; H U Schweikert
Journal:  Acta Endocrinol (Copenh)       Date:  1986-12

7.  Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.

Authors:  R E Peterson; J Imperato-McGinley; T Gautier; E Sturla
Journal:  Am J Med       Date:  1977-02       Impact factor: 4.965

8.  High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor.

Authors:  P Price; J A Wass; J E Griffin; M Leshin; M O Savage; D M Large; D E Bu'Lock; D C Anderson; J D Wilson; G M Besser
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

9.  Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal.

Authors:  P C Walsh; G M Hutchins; L L Ewing
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates.

Authors:  N Bruchovsky; P S Rennie; F H Batzold; S L Goldenberg; T Fletcher; M G McLoughlin
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

View more
  116 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation.

Authors:  J Zhang; S Zhang; P E Murtha; W Zhu; S S Hou; C Y Young
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

Review 3.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

4.  Regional distribution of 5α-reductase type 2 in the adult rat brain: an immunohistochemical analysis.

Authors:  M Paola Castelli; Alberto Casti; Angelo Casu; Roberto Frau; Marco Bortolato; Saturnino Spiga; Maria Grazia Ennas
Journal:  Psychoneuroendocrinology       Date:  2012-07-08       Impact factor: 4.905

5.  Androgenic correlates of genetic variation in the gene encoding 5alpha-reductase type 1.

Authors:  Justine A Ellis; Sianna Panagiotopoulos; Aysel Akdeniz; George Jerums; Stephen B Harrap
Journal:  J Hum Genet       Date:  2005-09-10       Impact factor: 3.172

6.  Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5α-Reductases.

Authors:  Hwei-Ming Peng; Juan Valentín-Goyco; Sang-Choul Im; Bing Han; Jiayan Liu; Jie Qiao; Richard J Auchus
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

7.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

8.  Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Authors:  Laura J Mosher; Sean C Godar; Marc Morissette; Kenneth M McFarlin; Simona Scheggi; Carla Gambarana; Stephen C Fowler; Thérèse Di Paolo; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2018-02-16       Impact factor: 4.905

9.  Dihydrotestosterone activates the MAPK pathway and modulates maximum isometric force through the EGF receptor in isolated intact mouse skeletal muscle fibres.

Authors:  M M Hamdi; G Mutungi
Journal:  J Physiol       Date:  2009-12-14       Impact factor: 5.182

10.  Serum LH correlates highly with intratesticular steroid levels in normal men.

Authors:  Mara Y Roth; K Lin; J K Amory; A M Matsumoto; B D Anawalt; C N Snyder; T F Kalhorn; W J Bremner; S T Page
Journal:  J Androl       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.